Clinical Trial Update: Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating individualized rituximab to maintain remission in moderate to severe systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Autoimmune Diseases | Phase 4 | Status: UNKNOWN